How big is DexCom, Inc.?

As of Jun 18, DexCom, Inc. has a market capitalization of $32.16 billion, with net sales of $4.15 billion and a net profit of $535.20 million over the latest four quarters.

Market Cap: As of Jun 18, DexCom, Inc. has a market capitalization of 32,159.81 million, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, DexCom, Inc. reported net sales of 4,148.00 million and a net profit of 535.20 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 2,102.60 million and total assets of 6,484.50 million.

What does DexCom, Inc. do?

DexCom, Inc. is a medical device company specializing in continuous glucose monitoring systems for diabetes management, with a market cap of approximately $32.16 billion. As of March 2025, it reported net sales of $1.036 billion and a net profit of $105 million.

Overview:<BR>DexCom, Inc. is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for people with diabetes, operating within the Pharmaceuticals & Biotechnology industry and classified as a large-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,036 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 105 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 32,159.81 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 64.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.10 <BR>Return on Equity: 23.61% <BR>Price to Book: 14.19<BR><BR>Contact Details:<BR>Address: 6340 Sequence Dr, SAN DIEGO CA: 92121-4356 <BR>Tel: 1 858 2000200 <BR>Website: http://www.dexcom.com

Should I buy, sell or hold DexCom, Inc.?

Who are in the management team of DexCom, Inc.?

As of March 2022, the management team of DexCom, Inc. includes Kevin Sayer as Chairman, President, and CEO, with Mark Foletta as Lead Independent Director and independent directors Steven Altman, Nicholas Augustinos, Richard Collins, and Karen Dahut.

As of March 2022, the management team of DexCom, Inc. includes Mr. Kevin Sayer, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Mr. Mark Foletta as the Lead Independent Director, along with independent directors Mr. Steven Altman, Mr. Nicholas Augustinos, Mr. Richard Collins, and Ms. Karen Dahut.

Is DexCom, Inc. technically bullish or bearish?

As of September 19, 2025, DexCom, Inc. shows a mildly bearish trend with mixed signals from MACD and moving averages, underperforming the S&P 500 significantly in recent periods.

As of 19 September 2025, the technical trend for DexCom, Inc. has changed from sideways to mildly bearish. The weekly MACD is bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are bearish, and the Bollinger Bands show a mildly bearish stance on the weekly and bearish on the monthly. Additionally, the Dow Theory indicates a mildly bearish trend for both weekly and monthly periods. <BR><BR>In terms of performance, DexCom has underperformed compared to the S&P 500 across multiple periods, with a 1-week return of -8.03% versus 1.22% for the S&P 500, and a year-to-date return of -10.62% compared to 13.31% for the benchmark. Overall, the current technical stance is mildly bearish, driven primarily by the bearish indicators in the moving averages and MACD on the weekly timeframe.

Is DexCom, Inc. overvalued or undervalued?

As of October 31, 2025, DexCom, Inc. is fairly valued with a P/E ratio of 64 and an EV to EBITDA of 39.43, but has underperformed the S&P 500 with a year-to-date return of -21.33%, suggesting a reassessment of its growth prospects compared to peers like Agilent Technologies.

As of 31 October 2025, the valuation grade for DexCom, Inc. moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 64, an EV to EBITDA of 39.43, and a Price to Book Value of 15.03. In comparison, Agilent Technologies, Inc. has a more attractive P/E ratio of 27.42 and an EV to EBITDA of 20.749, indicating that DexCom may be relatively overvalued against its peer.<BR><BR>Despite the fair valuation, DexCom has underperformed significantly compared to the S&P 500, with a year-to-date return of -21.33% versus the S&P 500's 16.30%. This underperformance over multiple periods suggests that investors may need to reassess their expectations regarding the company's growth prospects.